Cooperative Agreement N626451720001

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $288,515 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Integral Molecular Inc. for the development of a Rapid Reporter Virus (RRV) assay. The goal of this project is to create a streamlined, safe, and scalable alternative to traditional plaque reduction neutralization tests (PRNT) for assessing virus infection and neutralization. The RRV assay will leverage optical reporters...

This Cooperative Agreement award of $638,820 from the Defense Health Agency supports an mRNA multivalent approach to develop an innovative malaria vaccine. The project, funded through the Military Medical Research and Development program (CFDA 12.420), aims to broaden the immune targets against malaria infection by including both pre-erythrocytic-stage antigens and mosquito saliva antigens. The Geneva Foundation, a non-profit research organization, will conduct this research over a 3-year period...

This $288,360 federal Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop a novel vaccine candidate against multi-drug resistant Acinetobacter baumannii (MDR-AB). The Phase I project focuses on: (1) identifying and characterizing key immunogenic components of MDR-AB to induce protective immunity, (2) developing a prototype vaccine formulation, and (3) conducting...

The Defense Health Agency awarded a $456,633 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. The grant funds the development and optimization of a platform for next-generation monoclonal antibodies against Powassan virus and other neuroinvasive tick-borne viruses. Key collaborators include researchers from the United States Army Medical Research Institute of Infectious...

The Defense Health Agency awarded $780,749 to Health Research, Inc. Roswell Park Division under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research into novel combination immune therapy regimens for metastatic breast cancer. The three-year project grant, beginning February 1, 2023, will fund the development of innovative medical solutions through basic, applied, and advanced biomedical research. Specifically, the awardee will investigate new...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $7,994,888 Cooperative Agreement to RTI International to establish and maintain the Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (REVAMPP) Coordinating and Data Sharing Center (CDSC). The CDSC will coordinate and facilitate a collaborative network of 6-8 research centers focused on accelerating the discovery and dissemination of novel vaccine and antibody strategies to...

Health Research, Inc. Roswell Park Division received a $780,750 project grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on mechanisms of immune suppression and potential therapies. The three-year award, made on April 1, 2023, will support investigation into how the protein neuritin mediates reprogramming of myeloid cell populations and its role in immune suppression. Through this research, the awardee aims...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $650,156 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Board of Regents of the University of Nebraska to develop a novel multi-epitope protease cleavage site (MEPCS) vaccine for protecting against SIV rectal transmission. The project aims to comparatively evaluate the effectiveness of a cold-chain friendly and long-term stable MEPCS-mRNA-LNP vaccine versus an RVSV-MEPCS...

The Flavivirus and Alphavirus REVAMPP (FLARE) Center, funded by a $46,715,173 Cooperative Agreement from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research), is developing and optimizing protein nanoparticle, virion-based, and mRNA vaccine platforms, as well as monoclonal antibody-based treatments, to rapidly respond to emerging flaviviruses and alphaviruses with pandemic potential. The Center integrates the work of multiple academic...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $950,092 to Seattle Children's Hospital (dba Seattle Children's Research Institute) to develop targeted vaccine candidates against nontuberculous mycobacterial (NTM) infections. The research aims to create an adjuvanted subunit vaccine and a novel replicon RNA-based vaccine to improve immunity and prevent NTM...